The Miller Laboratory is dedicated to understanding neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and dementias in order to develop new, effective, and safe treatments. We focus on translational neuroscience, new therapeutic approaches for neurodegenerative diseases, and precision medicine.

WHAT WE DO

ALS Research

The Miller Lab seeks to understand the pathogenesis of ALS with basic studies focused on SOD1, C9ORF72, TBK-1,  miRNA, protein misfolding, protein kinetics, and genetic modifiers of disease. We employ RNA-targeted therapeutic strategies, mainly using antisense oligonucleotides.

Learn More

Dementia Research

The Miller Lab studies how the various isoforms of the protein tau affect neurodegeneration. We employ RNA-targeted therapeutic strategies using antisense oligonucleotides to develop therapies for dementias involving the tau protein as well as for TREM-2.

Learn More

LATEST NEWS

Prospective natural history study of_C9orf72ALS_clinical characteristics and biomarkers

January 15, 2020
Prospective natural history study of_C9orf72ALS_clinical characteristics and biomarkers Our team’s hard work has been published in Neurology. This paper profiles the clinical features, such as age at disease onset, survival duration, and measures of disease progression, of ALS patients with mutations in the C9orf72 gene. By defining the natural history of this patient population, this […]

New Diagnostic Test for Neurofilament

September 3, 2019
Biomarkers are measures reflective of biological processes that occur in the body. In the setting of disease, biomarkers may be used for diagnostic, prognostic or treatment monitoring purposes.

HOW YOU CAN HELP

Join our email list

Receive updates from the Miller Lab. 

Sign Up Now

Donate

Help develop new treatments, therapies and cures.

Donate Now